A Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno-Associated Virus.

The ability to target the adeno-associated virus (AAV) to specific types of cells, by altering the cell-surface receptor it binds, is desirable to generate safe and efficient therapeutic vectors. Chemical attachment of receptor-targeting agents onto the AAV capsid holds potential to alter its tropism, but is limited by the lack of site specificity of available conjugation strategies. The development of an AAV production platform is reported that enables incorporation of unnatural amino acids (UAAs) into specific sites on the virus capsid. Incorporation of an azido-UAA enabled site-specific attachment of a cyclic-RGD peptide onto the capsid, retargeting the virus to the αv β3 integrin receptors, which are overexpressed in tumor vasculature. Retargeting ability was site-dependent, underscoring the importance of achieving site-selective capsid modification. This work provides a general chemical approach to introduce various receptor binding agents onto the AAV capsid with site selectivity to generate optimized vectors with engineered infectivity.

[1]  A. Ting,et al.  Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Carolyn R Bertozzi,et al.  Introducing genetically encoded aldehydes into proteins. , 2007, Nature chemical biology.

[3]  Peng R. Chen,et al.  Introducing bioorthogonal functionalities into proteins in living cells. , 2011, Accounts of chemical research.

[4]  O. Danos,et al.  Deleterious effect of peptide insertions in a permissive site of the AAV2 capsid. , 2003, Virology.

[5]  M. Hallek,et al.  Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[7]  E. Zandi,et al.  Site-specific modification of adeno-associated viruses via a genetically engineered aldehyde tag. , 2013, Small.

[8]  S. Goodman,et al.  Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists , 1996 .

[9]  P. Schultz,et al.  A genetically encoded fluorescent probe in mammalian cells. , 2013, Journal of the American Chemical Society.

[10]  T. Wirth,et al.  History of gene therapy. , 2013, Gene.

[11]  J. Chin,et al.  Genetic Encoding of Bicyclononynes and trans-Cyclooctenes for Site-Specific Protein Labeling in Vitro and in Live Mammalian Cells via Rapid Fluorogenic Diels–Alder Reactions , 2012, Journal of the American Chemical Society.

[12]  Partha Sarathi Banerjee,et al.  Unnatural Amino Acid Incorporation onto Adenoviral (Ad) Coat Proteins Facilitates Chemoselective Modification and Retargeting of Ad Type 5 Vectors , 2011, Journal of Virology.

[13]  M. Kay.  State-of-the-art gene-based therapies: the road ahead , 2011, Nature Reviews Genetics.

[14]  M. Agbandje-McKenna,et al.  AAV capsid structure and cell interactions. , 2011, Methods in molecular biology.

[15]  Jennifer A. Prescher,et al.  A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. , 2004, Journal of the American Chemical Society.

[16]  Carsten Schultz,et al.  Amino acids for Diels-Alder reactions in living cells. , 2012, Angewandte Chemie.

[17]  Andrew B. Martin,et al.  Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. , 2002, Journal of the American Chemical Society.

[18]  Lin Li,et al.  Site-specific engineering of chemical functionalities on the surface of live hepatitis D virus. , 2013, Angewandte Chemie.

[19]  M. Howarth,et al.  Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase , 2005, Nature Methods.

[20]  Wei Zhang,et al.  A biosynthetic route to photoclick chemistry on proteins. , 2010, Journal of the American Chemical Society.

[21]  Michael T. Taylor,et al.  Genetically encoded tetrazine amino acid directs rapid site-specific in vivo bioorthogonal ligation with trans-cyclooctenes. , 2012, Journal of the American Chemical Society.

[22]  R. Samulski,et al.  AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. , 2014, Annual review of virology.

[23]  M. S. Chapman,et al.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Sharpless,et al.  Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  David V. Schaffer,et al.  Engineering adeno-associated viruses for clinical gene therapy , 2014, Nature Reviews Genetics.

[26]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[27]  J. Chin,et al.  Expanding and reprogramming the genetic code of cells and animals. , 2014, Annual review of biochemistry.

[28]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[29]  J. Chin,et al.  Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolysyl-tRNA Synthetase/tRNA(CUA) pair and click chemistry. , 2009, Journal of the American Chemical Society.

[30]  Partha Sarathi Banerjee,et al.  Chemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells. , 2010, Journal of the American Chemical Society.

[31]  A. Asokan,et al.  Glycated AAV vectors: chemical redirection of viral tissue tropism. , 2011, Bioconjugate chemistry.

[32]  J. Bartlett,et al.  RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  Peter G Schultz,et al.  Adding new chemistries to the genetic code. , 2010, Annual review of biochemistry.

[34]  Peter G Schultz,et al.  Protein conjugation with genetically encoded unnatural amino acids. , 2013, Current opinion in chemical biology.

[35]  C. Sheridan,et al.  Gene therapy finds its niche , 2011, Nature Biotechnology.

[36]  Jana L Phillips,et al.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle , 2010, Nature Biotechnology.